QuickView for cytochrome-b5 reductase activity, acting on NAD(P)H (biogroup)

1. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
2. MiRNA profiling during infection with H7N7 influenza A virus
3. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
4. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
5. L1000 CMAP - Breast adenocarcinoma SKBR3 cells treated with small molecule perturbagens

1. Comparison of NADH-dependent cytochrome b5 reductase activity and in vitro methemoglobin induction b…
2. NADH-dependent cytochrome b5 reductase and NADPH methemoglobin reductase activity in the erythrocyte…
3. Colon cancer chemopreventive efficacy of silibinin through perturbation of xenobiotic metabolizing e…
4. Recessive hereditary methemoglobinemia: two novel mutations in the NADH-cytochrome b5 reductase gene…
5. Expression and characterization of a functional canine variant of cytochrome b5 reductase.

There were no clinical trials for cytochrome-b5 reductase activity, acting on NAD(P)H